Clinical trials: Donors
ESRD, Hepatitis C
Live Kidney Donors With Positive Anti-HCV Antibody, But Negative HCV PCR
It is well recognized that a subset of patients who contracts Hepatitis C virus (HCV) spontaneously clears the virus. Such individuals are anti-HCV antibody positive, yet HCV RNA PCR negative in the blood.
- Trial name
- NCT02669966
- Testing
- Kidney transplantation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Florida
Brain Dead Organ Donors
Evaluation of the Efficacy and Safety of Levothyroxine in Brain Death Organ Donors: a Randomized Controled Trial
The primary objective of this study is to evaluate the feasibility of a randomized controlled trial comparing levothyroxine to placebo in neurologically deceased donors
- Trial name
- ECHOT4 (NCT02211053)
- Testing
- Levothyroxine
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Leukemia, Lymphoma
Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases
- Trial name
- NCT00055653
- Testing
- anti-thymocyte globulin, filgrastim, busulfan
- Where
- 25 sites in United States
- Sponsor
- Roswell Park Cancer Institute
Brain Damage Due to Hypoxia, Organ Donors
Endothelial Glycocalyx Damage in Brain Death Organ Donors
The study aims the assessment of endothelial glycocalyx (EG) degradation in deceased organ donors. There is a lack of organs for the transplantation program.
- Conditions
- Brain Damage Due to Hypoxia, Organ Donors, Organ Transplant Failure or Rejection
- Trial name
- NCT05609123
- Testing
- Endothelial glycocalyx damage assessment
- Where
- Czechia
- Volunteers
- 100 people
- Sponsor
- University Hospital Hradec Kralove
Hematologic Malignancies
G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome
The purposes of this study are: To examine the engraftment rate in patients receiving in vivo T-cell-depleted G-CSF stimulated bone marrow from partially mismatched related donors.
- Trial name
- G-CSF PMRD (NCT00228813)
- Testing
- Granulocyte Colony Stimulating Factor
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Emory University
Kidney Transplant Rejection
Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R)
Antibody mediated rejection (ABMR) is a major cause of graft loss after kidney transplantation (KT) and is mainly associated with preformed anti-HLA donor specific antibodies (DSAs) (phenotype 1) or de novo DSAs (dnDSAs)…
- Trial name
- BELA-M-R (NCT06291103)
- Testing
- Conversion to Belatacep, Standard of care treatment (SOC regimen) with Tacrolimus
- Where
- France
- Volunteers
- 290 people
- Sponsor
- University Hospital, Rouen
Sickle Cell Disease, Stem Cell Transplant Complications
Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor
The aim of this study to evaluate the safety and efficacy of a nonmyeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with sickle cell disease (SCD) who have a…
- Conditions
- Sickle Cell Disease, Stem Cell Transplant Complications, Red Blood Cell Disorder, Pure Red Cell Aplasia
- Trial name
- Sickle-AID (NCT03214354)
- Testing
- Alemtuzumab, Total Body Irradiation, Sirolimus
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University of Calgary
Hepatitis C, Heart Transplant
Expanding the Pool in Orthotopic Heart Transplantation
This is an open-label, pilot trial to test the safety and efficacy of transplantation of hearts from HCV seropositive non-viremic (HCV Ab+/NAT-) and HCV seropositive viremic (HCV Ab+/NAT+) donors to HCV seronegative recipients on…
- Conditions
- Hepatitis C, Heart Transplant, Cardiac Transplant
- Trial name
- NCT03222531
- Testing
- sofosbuvir/velpatasvir
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mary E. Keebler, MD
Liver Insufficiency
Metabolomics of Liver Regeneration Following Partial Hepatectomy in Healthy Living Liver Donors
The PI will study metabolism during liver regeneration in living liver donors
- Trial name
- NCT01922323
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Baylor Research Institute
Sickle Cell Disease
TMLI and Alemtuzumab for Treatment of Sickle Cell Disease
This phase I trial tests the safety and effectiveness of total marrow and lymphoid irradiation (TMLI) and alemtuzumab as a conditioning regimen in patients with sickle cell disease.
- Trial name
- NCT05384756
- Testing
- Alemtuzumab, Hematopoietic Cell Transplantation, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Chronic Kidney Disease (CKD), Kidney Transplant
Remote vs In-Person Prehabilitation for Kidney Transplant Candidates
Patients with advanced chronic kidney disease awaiting deceased-donor kidney transplantation frequently experience progressive functional decline, frailty, reduced mobility, and poor quality of life while on the transplant…
- Conditions
- Chronic Kidney Disease (CKD), Kidney Transplant, Frailty, Prehabilitation
- Trial name
- KIDFIT (NCT07701382)
- Testing
- In-Person Multimodal Prehabilitation, Remote Multimodal Prehabilitation
- Where
- Spain
- Volunteers
- 84 people
- Sponsor
- Hospital Clinic of Barcelona
Dengue
Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican and US Blood Donors - CTS
The objective of this study is to test individual donor samples (IDSs) with the investigational Dengue Assay on the TIGRIS System and to further characterize the Dengue Assay in the clinical setting.
- Trial name
- NCT01702272
- Testing
- Procleix Dengue Virus Assay
- Where
- United States
- Volunteers
- 150,000 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
Clostridium Difficile Infection, Fecal Microbiota Transplantation
The Dynamic Fluctuation of Donor Microbiota Affects the Prognosis of Fecal Microbiota Transplantation for C. Difficile Infection
Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the…
- Trial name
- NCT05703477
- Testing
- Fecal microbiota transplantation
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai 10th People's Hospital
Chronic Lymphocytic Leukemia, Graft vs Host Disease
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
Diseases such as leukemia, lymphoma, and multiple myeloma fall into the category of blood cancers. Some of these conditions can now be cured by bone marrow transplantation (BMT).
- Conditions
- Chronic Lymphocytic Leukemia, Graft vs Host Disease, Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00001637
- Testing
- Blood cell transplantation
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases
RATIONALE: Studying a diagnostic biomarker test in blood samples from patients who have undergone a donor stem cell transplant for cancer may help doctors plan treatment.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia
- Trial name
- NCT00813501
- Testing
- immunosuppressive therapy, immunological diagnostic method, allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- City of Hope Medical Center
Relapsed Hematologic Malignancy
Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant
The haematological neoplasia relapse is the cause of higher mortality after allogeneic stem cell transplantation (HSCT). When transplantation fails the most common therapeutic strategy is to increase the antitumor activity of the…
- Trial name
- Haplo-CIK (NCT03821519)
- Testing
- donor-derived CIK cells
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII
Leukemia, Lymphoma, Non-Hodgkin
Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
GVHD prophylaxis of sirolimus and mycophenolate mofetil for patients undergoing matched related allogeneic transplant for acute and chronic leukemia, MDS, high risk NHL and HL
- Conditions
- Leukemia, Lymphoma, Non-Hodgkin, Hematologic Diseases, Acute GVHD
- Trial name
- NCT00350181
- Testing
- Sirolimus, MMF, BCNU
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stanford University
End Stage Renal Disease
Desensitization Protocol for Highly Sensitized Patients on the Waiting List for Kidney Transplant
The purpose of this study is to determine whether high dose IVIG and B cell depleting agents can be used effectively in highly sensitized wait-listed patients.
- Trial name
- NCT01502267
- Testing
- High dose IVIG and B cell depleting agents
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- Seoul National University Hospital
Hodgkin's Lymphoma
Consolidation PET-based and Donor-based After Salvage Therapy in Patients With HL in Relapse or Refractory
PET-based consolidation and donor-based therapy after rescue in patients with Hodgkin's lymphoma refractory at first line therapy, or relapse early or late, undergone a second line chemotherapy.
- Trial name
- NCT00879528
- Testing
- Patients with negative PET after salvage therapy, Patients with positive PET after salvage therapy
- Where
- 39 sites in Italy
- Volunteers
- 264 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Breast Neoplasms, Neoplasms by Site
Studying Normal Breast Tissue and Cancer Risk
Breast cancer is the most common cancer among women in the United States. Breast cancer research has been hampered by the difficulty in collecting normal breast tissue.
- Conditions
- Breast Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases
- Trial name
- NCT00341692
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)